Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ana Fuentes

Nurse Practitioner Goodyear, AZ Nurse Practitioner

NPI 1053056523 CMS profile 11370686

14415 W McDowell Rd Ste D102, Goodyear, AZ 85395

Open in the dashboard

General payments

$1,693

69 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ana Fuentes of Goodyear, AZ is reported in the CMS Open Payments database as having received $1,693 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $115 4
2024 General $315 10
2023 General $766 32
2022 General $497 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ana Fuentes
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Ana Fuentes were reported at $115. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Ana Fuentes Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $497 $152 $48–$470 $149
2023 $766 $166 $54–$529 $160
2024 $315 $173 $55–$556 $164
2025 $115 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $393 13 payments
  2. Vertos Medical, Inc. $321 8 payments
  3. Collegium Pharmaceutical, Inc. $120 8 payments
  4. Pfizer Inc. $113 6 payments
  5. Nevro Corp. $102 3 payments
  6. Valinor Pharma, LLC $90 4 payments
  7. Nalu Medical, Inc. $88 5 payments
  8. Medtronic, Inc. $61 2 payments
  9. Scilex Pharmaceuticals Inc. $60 3 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $56 3 payments
  11. Other $287 14 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,672 68 payments
  2. Education $21 1 payment
Products named General payments · program years 2022–2025
  1. mild Device Kit $321 8 payments
  2. Entrada $118 1 payment
  3. NURTEC ODT Pain $113 6 payments
  4. XTAMPZA $104 7 payments
  5. Nalu Neurostimulation System $88 5 payments
  6. Omnia $68 2 payments
  7. INTELLIS ADAPTIVESTIM $61 2 payments
  8. ZTLido $60 3 payments
  9. Click $57 1 payment
  10. NURTEC ODT Primary Care $56 3 payments
  11. Other $489 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,160

Median for Nurse Practitioner: 389

Drug cost

$52,435

Median for Nurse Practitioner: $21,885

Branded share of claims

41.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 341 $11,719
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 337 $10,282
Gabapentin Generic 309 $4,902
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 81 $4,769
Pregabalin Generic 132 $3,966
Oxycodone Hcl Generic 208 $3,384
Diclofenac Sodium Generic 53 $1,766
Morphine Sulfate Er Morphine Sulfate Brand 65 $1,726
Tramadol Hcl Generic 121 $1,638
Tizanidine Hcl Generic 88 $913

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$25,010

Medicare's payments for the services billed

Medicare patients

109

Average age 72

Services billed

389

59 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 46%
Diabetes 43%
Ischemic heart disease 31%
Depression 28%
Heart failure 22%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record